Abbott, Takeda Conclude TAP Joint Venture
OSAKA, Japan, and ABBOTT PARK, Ill., May 01, 2008 /PRNewswire-FirstCall/ -- Abbott and Takeda Pharmaceutical Company Limited have concluded their TAP Pharmaceutical Products Inc. (TAP) joint venture.
The closing of the agreement to evenly divide the value of the more than 30-year-old joint venture marks the conclusion of one of the most successful joint ventures in the history of American business.
Under terms of the agreement, Abbott receives rights to the oncology treatment, Lupron, including the commercial organization supporting that franchise, and will receive payments based on TAP's other current and certain future products. Takeda receives the rights to the product Prevacid, all the remaining TAP commercial and support organizations, and the rights to TAP's pipeline.
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.
Private Securities Litigation Reform Act of 1995 A Caution Concerning Forward-Looking Statements
Some statements in this news release may be forward-looking statements for the purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to Abbott's Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2007, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.
Takeda, located in Osaka, Japan, is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders in the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, http://www.takeda.com/.
Takeda Forward-Looking Statement
This press release contains forward-looking statements regarding the Company's plans, outlook, strategies and results for the future. All forward-looking statements are based on judgments derived from the information available to the Company at this time. Certain risks and uncertainties could cause the Company's actual results to differ materially from any projections presented in this press release. These risks and uncertainties include, but are not limited to, the economic circumstances surrounding the Company's business; competitive pressure; relative laws and regulations; product development programs; and changes in exchange rates. We assume no obligation to update or reverse any forward-looking statements or other information contained in this presentation, whether as a result of new information, future events, or otherwise.
CONTACT: Media, Melissa Brotz, +1-847-935-3456, or Scott Stoffel,+1-847-936-9502, or Financial, John Thomas, +1-847-938-2655, all of Abbott;or Media, Matt Kuhn, +1-224-554-5609, or Financial, Tomoyuki Ooue,+81-3-3278-2301, , both of Takeda Ooue_Tomoyuki@takeda.co.jp
Ticker Symbol: (:ABT)
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: May 2008
Recommended for you